52例机器人二尖瓣置换术使用生物瓣膜:一家三级转诊医院的经验
本研究回顾了2013年1月至2017年5月在一家三级转诊医院连续52例使用da Vinci Si系统行机器人二尖瓣置换术并植入生物瓣的患者资料,平均年龄55.1±13.8岁,平均EuroSCORE II为2.25%±1.25%。结果显示无手术死亡,平均随访29±15个月期间无瓣膜退变,左房内径从51.4±11.5 mm显著降至42.6±10.1 mm。作者认为该技术安全、可行且可重复,中期结果令人鼓舞。
要点
- 连续52例机器人二尖瓣置换术使用生物瓣,无手术死亡。
- 38例(73.1%)同期行心脏手术,包括26例Cox-maze IV、12例三尖瓣修复和5例房间隔缺损修补。
- 平均随访29±15个月无瓣膜退变,左房内径从51.4±11.5 mm显著降至42.6±10.1 mm。
核心结论
- 作者认为机器人二尖瓣置换术使用生物瓣是安全、可行且可重复的,中期结果令人鼓舞。
- 作者指出主动脉阻断时间和体外循环时间可随经验积累而改善。
研究设计与样本
- 回顾性分析2013年1月至2017年5月在一家三级转诊医院连续52例使用da Vinci Si手术系统行机器人二尖瓣置换术并植入生物瓣的患者。
- 患者平均年龄55.1±13.8岁,平均EuroSCORE II为2.25%±1.25%。
- 32例(61.5%)术前存在心房颤动,6例(11.5%)有栓塞性卒中史,5例(9.6%)有既往心脏手术史。
- 手术在体外循环心脏停搏状态下进行。
主要发现
- 植入猪瓣5枚、牛瓣47枚;38例(73.1%)同期行心脏手术,包括26例Cox-maze IV、12例三尖瓣修复和5例房间隔缺损修补。
- 平均主动脉阻断时间141.3±34.3分钟,平均体外循环时间217.1±42.0分钟。
- 无手术死亡;平均随访29±15个月期间未见瓣膜退变。
- 左房内径平均值从51.4±11.5 mm显著降至42.6±10.1 mm。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Robotic mitral valve replacement (MVR) emerged in the late 1990s as an alternative approach to conventional sternotomy. With the increased use of bioprosthetic valves worldwide and strong patient desire for minimally invasive procedures, the safety and feasibility of robotic MVRs with bioprosthetic valves require investigation. METHODS: Between January 2013 and May 2017, 52 consecutive patients underwent robotic MVRs using the da Vinci Si surgical system (Intuitive Surgical Inc., Sunnyvale, CA, USA). Their mean age was 55.1 ± 13.8 years, and mean EuroSCORE II was 2.25% ± 1.25%. Among the enrolled patients, 32 (61.5%) patients presented with preoperative atrial fibrillation, 6 (11.5%) patients had experienced embolic stroke and 5 (9.6%) patients had undergone previous cardiac surgery. The operations were performed using cardiopulmonary bypass (CPB) under an arrested heart status. RESULTS: Five porcine valves and 47 bovine valves were implanted. A total of 38 (73.1%) patients received concomitant cardiac procedures, including 26 Cox-maze IV procedures, 12 tricuspid valve repairs and 5 atrial septal defect repairs. The mean aortic cross-clamp and CPB times were 141.3 ± 34.3 min and 217.1 ± 42.0 min, respectively. There was no operative mortality. During the mean follow-up of 29 ± 15 months, no prosthesis degeneration was noted. The average left atrial dimension exhibited a significant decrease from 51.4 ± 11.5 mm to 42.6 ± 10.1 mm. CONCLUSIONS: Robotic MVR with bioprosthetic valves is safe, feasible and reproducible. Mid-term results are encouraging. Both aortic cross-clamp and CPB times can be improved with experience.
引用
- Kuo CC, Chang HH, Hsing CH, et al. Robotic mitral valve replacements with bioprosthetic valves in 52 patients: experience from a tertiary referral hospital. Eur J Cardiothorac Surg. 2018. PMID: 29617931. doi:10.1093/ejcts/ezy134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。